Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,508.52 -116.71 (-0.17%) CMC Crypto 200
1,422.06 -6.51 (-0.46%)
IBRX Jan 2025 5.500 put
| Previous close | 1.5000 |
| Open | 1.5000 |
| Bid | 1.5500 |
| Ask | 1.8000 |
| Strike | 5.50 |
| Expiry date | 2025-01-17 |
| Day's range | 1.5000 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 419 |
Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
CULVER CITY, Calif., May 17, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company’s recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cancer research.
Simply Wall St.ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
ImmunityBio ( NASDAQ:IBRX ) First Quarter 2024 Results Key Financial Results Net loss: US$134.1m (loss widened by 15...
Business WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
CULVER CITY, Calif., May 07, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for "fill finish" (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg ANKTIVA (nogapendekin alfa inbakicept-pmln). Coupled with the recent announcement of a partnership with the Serum Institute of India (SII) for BCG availability, this provides the Company with a significant initial supply of ANKTIVA for commerc
